Cargando…

The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer

The antiandrogen enzalutamide (Enz) has improved survival in castration resistant prostate cancer (CRPC) patients. However, most patients eventually develop Enz resistance that may involve inducing the androgen receptor (AR) splicing variant 7 (ARv7). Here we report that high expression of monoamine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Keliang, Luo, Jie, Yeh, Shuyuan, You, Bosen, Meng, Jialin, Chang, Philip, Niu, Yuanjie, Li, Gonghui, Lu, Changxue, Zhu, Yezi, Antonarakis, Emmanuel S., Luo, Jun, Huang, Chi-Ping, Xu, Wanhai, Chang, Chawnshang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7264333/ https://www.ncbi.nlm.nih.gov/pubmed/32483206 http://dx.doi.org/10.1038/s41467-020-15396-5

Ejemplares similares

Overview of the Neuroprotective Effects of the MAO-Inhibiting Antidepressant Phenelzine
por: Matveychuk, Dmitriy, et al.
Publicado: (2021)

LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2/STAT3 signaling
por: Luo, Jie, et al.
Publicado: (2019)

Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer
por: Chou, Fu-Ju, et al.
Publicado: (2020)

Preclinical study using circular RNA 17 and micro RNA 181c-5p to suppress the enzalutamide-resistant prostate cancer progression
por: Wu, Gang, et al.
Publicado: (2019)

Preclinical studies show using enzalutamide is less effective in docetaxel-pretreated than in docetaxel-naïve prostate cancer cells
por: Lin, Changyi, et al.
Publicado: (2020)

Targeting androgen receptor (AR) with antiandrogen Enzalutamide increases prostate cancer cell invasion yet decreases bladder cancer cell invasion via differentially altering the AR/circRNA-ARC1/miR-125b-2-3p or miR-4736/PPARγ/MMP-9 signals
por: Deng, Gang, et al.
Publicado: (2021)

Androgen receptor promotes renal cell carcinoma (RCC) vasculogenic mimicry (VM) via altering TWIST1 nonsense-mediated decay through lncRNA-TANAR
por: You, Bosen, et al.
Publicado: (2021)

Suppressing BCL-XL increased the high dose androgens therapeutic effect to better induce the Enzalutamide-resistant prostate cancer autophagic cell death
por: Xiang, Zhendong, et al.
Publicado: (2021)

AR Splicing Variants and Resistance to AR Targeting Agents
por: Kanayama, Mayuko, et al.
Publicado: (2021)

Targeting the androgen receptor to enhance NK cell killing efficacy in bladder cancer by modulating ADAR2/circ_0001005/PD-L1 signaling
por: Liu, Qing, et al.
Publicado: (2022)

TNF signaling mediates an enzalutamide-induced metastatic phenotype of prostate cancer and microenvironment cell co-cultures
por: Sha, Kai, et al.
Publicado: (2015)

The miR-361-3p increases enzalutamide (Enz) sensitivity via targeting the ARv7 and MKNK2 to better suppress the Enz-resistant prostate cancer
por: Liu, Bianjiang, et al.
Publicado: (2020)

Enzalutamide in chemo-naïve castration-resistant prostate cancer: effective for most but not for all
por: Maughan, Benjamin L, et al.
Publicado: (2014)

Clorgyline Analogs Synergize with Azoles against Drug Efflux in Candida auris
por: Toepfer, Stephanie, et al.
Publicado: (2023)

High-dose-androgen-induced autophagic cell death to suppress the Enzalutamide-resistant prostate cancer growth via altering the circRNA-BCL2/miRNA-198/AMBRA1 signaling
por: Chen, Lei, et al.
Publicado: (2022)

Preclinical Study Using ABT263 to Increase Enzalutamide Sensitivity to Suppress Prostate Cancer Progression Via Targeting BCL2/ROS/USP26 Axis Through Altering ARv7 Protein Degradation
por: Xu, Hua, et al.
Publicado: (2020)

Preclinical study using androgen receptor (AR) degradation enhancer to increase radiotherapy efficacy via targeting radiation-increased AR to better suppress prostate cancer progression
por: Chou, Fu-Ju, et al.
Publicado: (2019)

Targeting the Lnc-OPHN1-5/androgen receptor/hnRNPA1 complex increases Enzalutamide sensitivity to better suppress prostate cancer progression
por: Zhang, Meng, et al.
Publicado: (2021)

Enzalutamide: the emperor of all anti-androgens
por: Antonarakis, Emmanuel S.
Publicado: (2013)

MAO-A Inhibition by Metaxalone Reverts IL-1β-Induced Inflammatory Phenotype in Microglial Cells
por: Pallio, Giovanni, et al.
Publicado: (2021)

ASC-J9® suppresses prostate cancer cell proliferation and invasion via altering the ATF3-PTK2 signaling
por: Tian, Hao, et al.
Publicado: (2021)

BM-MSCs promote prostate cancer progression via the conversion of normal fibroblasts to cancer-associated fibroblasts
por: WEN, SIMENG, et al.
Publicado: (2015)

Efficacy of Abiraterone and Enzalutamide in Pre- and Postdocetaxel Castration-Resistant Prostate Cancer: A Trial-Level Meta-Analysis
por: Fang, Mike, et al.
Publicado: (2017)

Administration of supplemental L-tyrosine with phenelzine: a clinical literature review
por: Hinz, Marty, et al.
Publicado: (2014)

A Selective Phenelzine Analogue Inhibitor of Histone Demethylase LSD1
por: Prusevich, Polina, et al.
Publicado: (2014)

A Case of the Serotonin Syndrome Secondary to Phenelzine Monotherapy at Therapeutic Dosing
por: Malik, A., et al.
Publicado: (2015)

Metabolic Effects of Oral Phenelzine Treatment on High-Sucrose-Drinking Mice
por: Carpéné, Christian, et al.
Publicado: (2018)

Phenelzine treatment increases transcription factor AP-2 levels in rat brain
por: Damberg, Mattias, et al.
Publicado: (2003)

Administration of Supplemental L-Tyrosine with Phenelzine: a Clinical Literature Review [Retraction]
Publicado: (2021)

Targeting the radiation-induced ARv7-mediated circNHS/miR-512-5p/XRCC5 signaling with Quercetin increases prostate cancer radiosensitivity
por: Chen, Dong, et al.
Publicado: (2022)

Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions
por: Tucci, Marcello, et al.
Publicado: (2018)

Targeting TR4 nuclear receptor with antagonist bexarotene increases docetaxel sensitivity to better suppress the metastatic castration-resistant prostate cancer progression
por: Hu, Linyi, et al.
Publicado: (2019)

Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer
por: Culig, Zoran
Publicado: (2017)

Molecular mechanisms of enzalutamide resistance in prostate cancer
por: Blatt, Eliot B., et al.
Publicado: (2019)

Monoamine Oxidase-A Occupancy by Moclobemide and Phenelzine: Implications for the Development of Monoamine Oxidase Inhibitors
por: Chiuccariello, Lina, et al.
Publicado: (2015)

Phase 2 Trial of Monoamine Oxidase Inhibitor Phenelzine in Biochemical Recurrent Prostate Cancer
por: Gross, Mitchell E., et al.
Publicado: (2020)

Administration of Supplemental L-Tyrosine with Phenelzine: A Clinical Literature Review [Expression of Concern]
Publicado: (2020)

Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer
por: Golshayan, Ali R, et al.
Publicado: (2013)

Targeting the ERβ/Angiopoietin-2/Tie-2 signaling-mediated angiogenesis with the FDA-approved anti-estrogen Faslodex to increase the Sunitinib sensitivity in RCC
por: Gu, Junfei, et al.
Publicado: (2020)

S-Nitrosoglutathione Reverts Dietary Sucrose-Induced Insulin Resistance
por: Sousa-Lima, Inês, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_l406ssrdi1vge8d7ma6val0rid